IP Library Granted Patent US 6,967,239
Granted Patent B1
US 6,967,239 · App. 09/581,398 · Granted Nov 22, 2005

Method of filtering viruses from a factor VIII solution

Assignee: Laboratoire Francias du Franctionnement et des Biotechnologies
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,967,239
App. No.
09/581,398
Granted
Nov 22, 2005
Kind
B1
Abstract

Method for preparing a factor VIII solution that is essentially free of viruses and essentially devoid of vWF (von Willebrand factor) and factor VIII-vWF complexes by (a) obtaining a starting factor VIII solution devoid of factor VIII-vWF complexes; and (b) filtering the solution through a hydrophilic virus filter.

Claims (17)

1. A method for preparing a factor VIII solution comprising:

(a) obtaining a starting factor VIII solution comprising factor VIII-von Willebrand factor (factor VIII-vWF) complexes; and

(b) filtering said solution through a hydrophilic virus filter, wherein the virus filter has a mean pore size of 13 to 17 nm and

wherein the filtering occurs in the presence of CaCl 2 ions, at a pressure of less than 0.3 bar and a temperature of about 35±5° C.; and

wherein the filtered solution is free of viruses and devoid of high molecular forms of vWF and factor VIII-vWF complexes.

2. The method according to claim 1 , wherein the CaCl 2 is present in the solution from 0.2 M to saturation.

3. The method according to claim 1 , wherein the starting factor VIII solution is treated with an effective amount of an anti-viral solvent, a detergent, or both.

4. The method according to claim 1 , wherein the starting factor VIII solution is immunopurified.

5. The method according to claim 1 , wherein the starting factor VIII solution comprises recombinantly produced factor VIII.

6. The method according to claim 1 , wherein the starting factor VIII solution of (a) is derived from a cryoprecipitated fraction of plasma.

7. The method according to claim 6 , wherein the starting factor VIII solution is obtained by a further heparin precipitation.

8. The method according to claim 1 , wherein the CaCl 2 is present in the solution from 0.35 M to saturation.

9. The method according to claim 8 , wherein the filter has a pore size of 15 nanometers.

10. The method according to claim 8 , wherein the filter is used at a pressure lower than 0.2 bar.

11. The method according to claim 1 , further comprising dissociating factor VIII-vWF complexes of the starting solution prior to (b) filtering.

12. The method according to claim 11 , wherein the factor VIII-vWF complexes of the starting factor VIII solution are dissociated by ion exchange chromatography.

13. The method according to claim 12 , wherein the starting factor VIII solution of (a) is derived from a cryoprecipitated fraction of plasma.

Assignments (2)
LICENSE Recorded Mar 11, 2009
From: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
To: LFB BIOMEDICAMENTS
Reel/Frame 022378/0273 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2000
From: KOGRE, MICHEL; PORTE, PIERRE; CHTOUROU,ABDESSATAR (SAMI)
To: LABORATOIRE FRANCIAS DU FRANCTIONNEMENT ET DES BIOTECHNOLOGIES
Reel/Frame 011025/0118 →
Priority Claims (1)
FR 97 15888 · Dec 15, 1997 · national